PBYI (Puma Biotechnology) Shiller PE Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBYI Puma Biotechnology Inc PBYI
53 GF Score
Price $7.69
GF Value $3.34
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Puma Biotechnology Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Puma Biotechnology  (NAS:PBYI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Puma Biotechnology Shiller PE Ratio Related Terms


Puma Biotechnology Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Puma Biotechnology's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Puma Biotechnology Shiller PE Ratio Chart

Puma Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Puma Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PBYI vs EVMN, OCGN, EDIT: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Puma Biotechnology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Puma Biotechnology Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Puma Biotechnology's Shiller PE Ratio falls into.


PBYI
53GF Score
Puma Biotechnology Inc PBYI
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Puma Biotechnology Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Puma Biotechnology's E10 for the quarter that ended in Mar. 2026 is calculated as:

For example, Puma Biotechnology's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.07/330.2130*330.2130
=-0.070

Current CPI (Mar. 2026) = 330.2130.

Puma Biotechnology Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201606 -2.050 241.018 -2.809
201609 -2.020 241.428 -2.763
201612 -2.040 241.432 -2.790
201703 -1.970 243.801 -2.668
201706 -2.100 244.955 -2.831
201709 -2.070 246.819 -2.769
201712 -1.710 246.524 -2.291
201803 -0.650 249.554 -0.860
201806 -1.170 251.989 -1.533
201809 -0.370 252.439 -0.484
201812 -0.800 251.233 -1.051
201903 -0.260 254.202 -0.338
201906 -0.970 256.143 -1.250
201909 -0.440 256.759 -0.566
201912 -0.290 256.974 -0.373
202003 -0.430 258.115 -0.550
202006 0.080 257.797 0.102
202009 -0.790 260.280 -1.002
202012 -0.380 260.474 -0.482
202103 0.400 264.877 0.499
202106 -0.130 271.696 -0.158
202109 -1.090 274.310 -1.312
202112 0.100 278.802 0.118
202203 -0.080 287.504 -0.092
202206 0.210 296.311 0.234
202209 -0.010 296.808 -0.011
202212 -0.120 296.797 -0.134
202303 0.030 301.836 0.033
202306 0.050 305.109 0.054
202309 0.120 307.789 0.129
202312 0.250 306.746 0.269
202403 -0.100 312.332 -0.106
202406 -0.090 314.175 -0.095
202409 0.410 315.301 0.429
202412 0.390 315.605 0.408
202503 0.060 319.799 0.062
202506 0.120 322.561 0.123
202509 0.170 324.800 0.173
202512 0.260 324.054 0.265
202603 -0.070 330.213 -0.070

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Puma Biotechnology (PBYI) Overvalued in 2026?

Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued. The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34. GuruFocus considers Puma Biotechnology to be Significantly Overvalued.

Key valuation signals for PBYI:

  • Shiller PE Ratio:
  • GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Puma Biotechnology Business Description

Address 10880 Wilshire Boulevard, Suite 1700, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score

Get the complete analysis for PBYI

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.69
Price
$3.34
GF Value